Why Is Exact Sciences Stock Trading Higher On Monday?
Why Is Exact Sciences Stock Trading Higher On Monday?
On Monday, the Centers for Medicare & Medicaid Services posted final payment determinations for its 2025 Clinical Laboratory Fee Schedule.
周一，医疗保险和医疗补助服务中心公布了2025年临床实验室费用表的最终支付决定。
Included was a final decision related to CMS pricing for Exact Sciences Corp's (NASDAQ:EXAS) Cologuard Plus, a second-generation test that received FDA approval in October.
其中包括与康哲药业对精密科学公司(NASDAQ:EXAS) 的Cologuard Plus定价相关的最终决定，该测试是获得FDA批准的第二代检测，批准时间为十月。
William Blair writes that the determinations effectively raise reimbursement by 16% versus the current Medicare rate for the first-generation Cologuard test (to $592 for Cologuard Plus from $509 for Cologuard).
威廉·布莱尔表示，这些决定有效地提高了相较于当前医疗保险首代Cologuard测试的报销率，增幅为16%（Cologuard Plus 从509美元提高到592美元）。
Also Read: Colorectal Cancer Diagnostic Focused Exact Sciences Stock Plunges On Weak Annual Guidance, Analyst Sees Compelling Long-Term Entry Point
另请阅读：聚焦结直肠癌诊断的精密科学股价因年度指引疲弱而暴跌，分析师认为这是一个引人注目的长期入场点。
The determination reverses the September preliminary decision but aligns with a proposal made during the public comment period.
该决定推翻了九月份的初步决定，但与公众评论期间提出的建议一致。
The analyst writes that reimbursement for Cologuard Plus will now be calculated based on two components: three times the fee for methylation analysis of Septin-9 ($192 x 3) and the fee for a FIT test ($15.92).
分析师写道，Cologuard Plus的报销将基于两个元件计算：Septin-9的甲基化分析费用的三倍（192美元 x 3）和FIt测试的费用（15.92美元）。
This pricing adjustment is expected to take effect for Medicare volumes when the test officially launches in late first quarter or early second quarter of 2025. Medicare fee-for-service volumes should reflect the new pricing immediately upon launch, with Medicare Advantage following soon after.
预计这一定价调整将在测试于2025年第一季度末或第二季度初正式推出后生效。医疗保险按服务收费的卷宗应在推出时立即反映新定价，医疗保险优势计划随后也会迅速跟进。
The company is also likely to renegotiate commercial contracts for higher pricing, which may gradually roll out over the coming quarters and years.
公司可能还会重新谈判商业合同以获取更高的定价，这可能会在接下来的季度和多年内逐步推出。
William Blair reiterates the Outperform rating on the stock.
William Blair重申对该股票的优于大盘评级。
The analyst highlights that the update is a positive outcome for the company, as it simplifies the process of implementing a price increase compared to the more complex advanced diagnostic laboratory test (ADLT) pathway.
分析师指出，这次更新对公司来说是一个积极结果，因为相比于更复杂的爱文思控股诊断实验室测试（ADLT）路径，这简化了实施价格上涨的过程。
From a financial perspective, this decision is expected to support a moderate pricing boost starting in 2025. Based on William Blair's estimates, this could add at least 300 basis points to Cologuard's growth rate next year, which is projected to be around 15% overall.
从财务角度来看，预计这一决定将支持在2025年开始进行温和的价格提升。根据William Blair的估计，这可能使Cologuard的增长率在明年增加至少300个基点，预计整体增长率约为15%。
Exact Sciences said it will present 10 abstracts demonstrating the breadth of its Precision Oncology portfolio at the 2024 annual San Antonio Breast Cancer Symposium scheduled next month.
精密科学表示，将在下月举行的2024年圣安东尼奥乳腺癌年会上展示10篇摘要，展示其精准肿瘤学产品组合的广度。
Price Action: EXAS stock is up 7.60% at $59.33 at last check Tuesday.
价格动态：EXAS股票在周二最后检查时上涨了7.60%，达到了59.33美元。
- Analog Devices Q4 Earnings: Beats Estimates, Automotive Rebound, Cautiously Optimistic Outlook & More
- 亚德诺第4季度收益：超出预期，汽车市场复苏，谨慎乐观的前景及更多
Illustration of Phrama lab worker created with MidJourney.
药厂实验室工作者插图，由MidJourney创建。
